Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | ESRRA | P11474 | 2/20 | 0.37 |
| ▸ | ESRRB | O95718 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18608951 | 0.83 | CHRM2 (0.44) | CHRM2CHRM3MAPTNPC1RAB9A | |
| SCHEMBL5049416 | 0.81 | CHRM2 (0.43) | CHRM2CHRM3MAPTNPC1RAB9A | |
| SCHEMBL14294672 | 0.81 | CHRM2 (0.45) | CHRM2CHRM3MAPTNPC1RAB9A | |
| SCHEMBL18590273 | 0.79 | ALDH1A1 (0.42) | CHRM2CHRM3MAPTNPC1RAB9A | |
| SCHEMBL18598425 | 0.77 | CHRM2 (0.40) | CHRM2CHRM3HSD17B10ALDH1A1TP53 | |
| SCHEMBL21412297 | 0.77 | AOC3 (0.47) | CHRM2CHRM3MAPTNPC1RAB9A | |
| SCHEMBL7085169 | 0.76 | MTOR (0.46) | MAPTNPC1RAB9ASMN1; SMN2ESR1 | |
| SCHEMBL23718615 | 0.71 | AOC3 (0.51) | — | |
| SCHEMBL23718611 | 0.71 | AOC3 (0.51) | — | |
| SCHEMBL21051373 | 0.70 | ACSS2 (0.43) | MAPTNPC1RAB9ASMN1; SMN2STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138840-B1 | THIADIAZOLIDINE DERIVATIVE AS ANTI-ENTEROVIRUS 71 | JIANGSU KANION PHARMACEUTICAL CO LTD (CN) | 2020-09-23 | — | — | EP | disclosed |
| CN-106661009-B | Anti- enteric virus71 thiadiazolidine derivative | 江苏康缘药业股份有限公司 | 2019-11-26 | — | — | CN | disclosed |
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| EP-3138840-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion Pharmaceutical Co., Ltd. (CN) | 2017-03-08 | — | — | EP | disclosed |
| CN-105085512-A | Enteric virus 71 (EV71)-resistant thiadiazolidine derivatives | NANJING MINGDE NEW DRUG RES AND DEV CO LTD | 2015-11-25 | — | — | CN | disclosed |
| WO-2015165340-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | 南京明德新药研发股份有限公司 | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | EIF2AK2, GTF3C5, GTF3C1 | CHRM2 4846/4885CHRM3 4827/4885MAPT 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.